Light-activated AU-011 for the treatment of primary choroidal melanoma was well tolerated with no severe adverse events, while showing promising early efficacy results, in a phase 1b/2 trial, Aura Biosciences announced in a press release.
The open-label, multicenter trial is evaluating the safety and efficacy of single and multiple ascending doses of AU-011 in 30 adult patients with small to medium primary choroidal melanoma.
Interim data showed two subjects in the first multiple-ascending-dose cohort had evidence of tumor reduction after 3 months, the release said. In addition, subtherapeutic
Uncategorized